Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs. A common biological phenomenon.

Literature DB >> 6788892

Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs. A common biological phenomenon.

M Goto, A Mitsuoka, M Sugiyama, M Kitano.

Abstract

Delayed hypersensitivity reaction in mice was commonly enhanced with various anti-cancer agents administered as single or intermittent high doses but not consecutive divided doses. The effect of anti-cancer agents on the delayed hypersensitivity reaction was thought to be due to elimination of suppressor T cell activity.

Entities: Disease Species

Mesh：

Substances：

Year: 1981 PMID： 6788892 PMCID： PMC2186397 DOI： 10.1084/jem.154.1.204

Source DB: PubMed Journal: J Exp Med ISSN： 0022-1007 Impact factor: 14.307

22 in total

1. Participation of cyclophosphamide-sensitive T cells in graft-vs-host reactions.

Authors: A Schwartz; S Orbach-Arbouys; R K Gershon
Journal: J Immunol Date: 1976-09 Impact factor: 5.422

2. Preferential development by mice of delayed hypersensitivity to purified basic proteins.

Authors: A J Crowle; A Patrucco
Journal: J Allergy Date: 1968-09

3. Comparative effects of selected cytotoxic agents on transplanted hematopoietic cells.

Authors: L L Sensenbrenner; A H Owens; L S Zawatzsky; G J Elfenbein
Journal: Transplantation Date: 1972-09 Impact factor: 4.939

Review 4. Combination cancer therapy: Presidential address.

Authors: E Frei
Journal: Cancer Res Date: 1972-12 Impact factor: 12.701

5. Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide.

Authors: J L Turk; D Parker; L W Poulter
Journal: Immunology Date: 1972-10 Impact factor: 7.397

6. Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer.

Authors: I Djerassi; C J Rominger; J S Kim; J Turchi; U Suvansri; D Hughes
Journal: Cancer Date: 1972-07 Impact factor: 6.860

Review 7. Enzyme induction (second of three parts).

Authors: T D Gelehrter
Journal: N Engl J Med Date: 1976-03-11 Impact factor: 91.245

8. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo.

Authors: W R Bruce; B E Meeker; F A Valeriote
Journal: J Natl Cancer Inst Date: 1966-08 Impact factor: 13.506

9. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma.

Authors: G Rosen; C Tan; A Sanmaneechai; E J Beattie; R Marcove; M L Murphy
Journal: Cancer Date: 1975-03 Impact factor: 6.860

10. Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide.

Authors: P H Lagrange; G B Mackaness; T E Miller
Journal: J Exp Med Date: 1974-06-01 Impact factor: 14.307

13 in total

1. Synergistic effects of locally administered cytostatic drugs and a surfactant on the development of delayed-type hypersensitivity to keyhole limpet haemocyanin in mice.

Authors: J Limpens; R J Scheper
Journal: Clin Exp Immunol Date: 1989-11 Impact factor: 4.330

2. Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation.

Authors: A M Claessen; H Valster; H Bril; S Meyer; R J Scheper
Journal: Cancer Immunol Immunother Date: 1989 Impact factor: 6.968

Review 3. Modulation of antitumor immunity--immunobiologic approaches.

Authors: R J North; E S Dye; C D Mills; J P Chandler
Journal: Springer Semin Immunopathol Date: 1982

4. Host defence mechanisms, antibiotics and immunosuppressive agents--a complex relationship.

Authors: T E Miller
Journal: Eur J Clin Microbiol Date: 1984-08 Impact factor: 3.267

5. Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.

Authors: L M Weiner; G R Hudes; J Kitson; J Walczak; P Watts; S Litwin; P J O'Dwyer
Journal: Cancer Immunol Immunother Date: 1993 Impact factor: 6.968

6. Evaluation of various cytostatic drugs as local immunotherapeutic agents.

Authors: R J Scheper; A Vos; J de Groot; G H Boerrigter
Journal: Invest New Drugs Date: 1984 Impact factor: 3.850

7. Local administration of cytostatic drug 4-hydroperoxy-cyclophosphamide (4-HPCY) facilitates cell-mediated immune reactions.

Authors: G H Boerrigter; R J Scheper
Journal: Clin Exp Immunol Date: 1984-10 Impact factor: 4.330

8. Cyclosporin A prevents suppression of delayed-type hypersensitivity in mice immunized with high-dose sheep erythrocytes.

Authors: L M Webster; A W Thomson
Journal: Immunology Date: 1987-03 Impact factor: 7.397

9. Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice.

Authors: H Shindo; T Ogura; T Masuno; S Hayashi; S Kishimoto
Journal: Cancer Immunol Immunother Date: 1985 Impact factor: 6.968

10. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.

Authors: M Awwad; R J North
Journal: Immunology Date: 1988-09 Impact factor: 7.397